News | Artificial Intelligence | October 20, 2020

Ezra's Prostate AI is the first to be cleared by the FDA

Ezra, a NY-based startup transforming early cancer screening using magnetic resonance imaging (MRI), announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence, designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first prostate AI to be cleared by the FDA.

October 20, 2020 — Ezra, a NY-based startup transforming early cancer screening using magnetic resonance imaging (MRI), announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence, designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first prostate AI to be cleared by the FDA.

Due to the increased efficiency that Prostate AI will generate for partner radiologists, Ezra is decreasing the price of the Ezra Prostate Scan by 15%, to $575.

"Over the past two years, our team has worked tirelessly on building Ezra's Prostate AI and I'm thrilled to bring it to our imaging partners across the US," said Emi Gal, CEO and co-founder of Ezra. "We will continue to work towards making the interpretation of prostate MRI scans faster and more affordable, in order to support the millions of men who are at risk of prostate cancer."

The Ezra AI achieves three important goals:

  • Accurate prostate volume measurements. Accurate prostate volume is critical to diagnosis because the size of the prostate is often an indication of potential disease.
  • Semi-automatic lesion measurements. Under current processes, if a lesion is identified in the prostate, a radiologist has to manually measure the size of the lesion, and grade it using the PI-RADS methodology. The Ezra Prostate AI automatically measures the size of a lesion saving time and minimizing patient worry.
  • Automatic prostate and lesion segmentation and 3D volume representation. Should a lesion require a biopsy, the Ezra Prostate AI automatically segments the prostate gland and the lesion for the radiologist for greater accuracy and precision.

To integrate Prostate AI into radiology workflows, Ezra has also obtained FDA clearance for Plexo, a cloud-based PACS (Picture Archiving and Communications System) that works directly in the browser. This means that radiologists can now log onto the Ezra platform and use the AI without the need to install any software.

"Ezra is at the forefront of MRI-based cancer screening, and the company's 510k FDA clearance for its Prostate interpretation AI is further validation of its innovation capabilities," said Lawrence Tanenbaum, M.D., FACR, Vice president and CTO, Director of MRI, CT and Advanced Imaging at RadNet.

Ezra launched its MRI-based prostate cancer screening program in January 2019, and rolled out its full-body MRI scan in May 2019. Ezra partners with existing outpatient imaging facilities, and all Ezra scans are analyzed by board-certified radiologists. The company's cancer screening programs are live in New York City, San Francisco, and Los Angeles through its partnership with RadNet, Inc., the nation's leader in outpatient imaging. In 2019, Ezra helped 4% of its members - all of whom were asymptomatic - detect cancer.  

In June, the company announced Ezra COVID 360, a low-dose CT scan of the lungs to look for damage caused by COVID-19, paired with an antibody blood test to check for igG and igM antibodies. The new plan is designed for individuals who want to understand the potential long-term impact of COVID-19 on their lung health and check their antibody status. Ezra COVID 360 is currently available for $390 in New York and California.

For more information: www.ezra.com


Related Content

News | Magnetic Resonance Imaging (MRI)

July 2, 2025 — Philips has received FDA 510(k) clearance for SmartSpeed Precise[1] MR’s latest deep learning ...

Time July 03, 2025
arrow
Feature

A new study published in JCO Clinical Cancer Informatics tackles a critical challenge in cancer diagnostics: ensuring ...

Time July 01, 2025
arrow
News | Ultrasound Imaging

July 1, 2025 — UPDATE: The final paper is now available at: JMIR AI - ChatGPT-4–Driven Liver Ultrasound Radiomics ...

Time July 01, 2025
arrow
News | Magnetic Resonance Imaging (MRI)

June 26, 2025 — Siemens Healthineers has received Food and Drug Administration clearance for the Magnetom Flow.Ace, its ...

Time June 26, 2025
arrow
News | Prostate Cancer

June 26, 2025 – Quibim, a global provider of quantitative medical imaging solutions, has launched AI-QUAL, a new feature ...

Time June 26, 2025
arrow
News | Image Guided Radiation Therapy (IGRT)

June 25, 2025 — Royal Philips and Indiana-based Methodist Hospitals recently announced the healthcare provider’s ...

Time June 25, 2025
arrow
News | Bone Densitometry Systems

June 19, 2025 — Naitive Technologies has published results demonstrating the diagnostic performance of its AI-powered ...

Time June 18, 2025
arrow
News | Lung Imaging

June 18, 2025 — Exo recently announced that now included on its Exo Iris is the first ever FDA 510(k) cleared AI for ...

Time June 18, 2025
arrow
News | Digital Pathology

June 11, 2025 — Diagnostic laboratory leaders view digital pathology and artificial intelligence (AI) as pivotal to ...

Time June 12, 2025
arrow
News | Lung Imaging

June 11, 2025 — To prepare healthcare workforces and providers for an AI-driven future, Qure.ai has expanded its Global ...

Time June 11, 2025
arrow
Subscribe Now